BIOSPHERIX LAUNCHES CENTER FOR CYTOCENTRIC® TECHNOLOGY IN PARISH, NY
In This Article
Key features of CCT:
GMP-level CDMO/CRO services for cell and gene therapy development
Integration of the Xvivo System GMP X2 for closed, controlled, and Cytocentric environmental control
Precise regulation of oxygen, carbon dioxide, temperature, humidity, and limit control measurements for particles, VHPs, and VOCs
Strategic proximity to the growing biotechnology hubs in Syracuse and Rochester NY
Ribbon-cutting to take place April 2026
The Big Picture
“The opening of the Center for Cytocentric® Technology marks a pivotal step forward for both BioSpherix and the broader cell and gene therapy community. By utilizing our Xvivo System® to provide GMP-level CDMO and CRO services in a fully closed, physiologically accurate environment, we are redefining how advanced therapies can be developed and manufactured. Our goal is to provide innovators across upstate New York and beyond with direct access to scalable, reproducible, and truly Cytocentric solutions that improve both scientific outcomes and patient impact.” – Syed Ahmed Mustafa, President/CEO of BioSpherix
